=> d his

(FILE 'HOME' ENTERED AT 14:35:09 ON 11 MAY 2005)

FILE 'CASREACT' ENTERED AT 14:35:21 ON 11 MAY 2005

L1 STRUCTURE UPLOADED

L2 3 S L1 SSS


L3 48 S L1 SSS FULL

L4 0 S L3 AND HEEL

=> d 11

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=>

=> d his

(FILE 'HOME' ENTERED AT 14:35:09 ON 11 MAY 2005)

FILE 'CASREACT' ENTERED AT 14:35:21 ON 11 MAY 2005

L1 STRUCTURE UPLOADED

L2 3 S L1 SSS

L3 48 S L1 SSS FULL

L4 0 S L3 AND HEEL

=> d 13 1-48

L3 ANSWER 1 OF 48 CASREACT COPYRIGHT 2005 ACS on STN

RX(13) OF 269

85%

REF: Bioorganic & Medicinal Chemistry Letters, 14(10), 2451-2457; 2004

L3 ANSWER 2 OF 48 CASREACT COPYRIGHT 2005 ACS on STN

REF: Journal of Organic Chemistry, 68(24), 9406-9411; 2003 NOTE: combinatorial, solid-supported reaction, attachment to Rink amide resin in stage one, Staudinger redn. in stage 3

L3 ANSWER 3 OF 48 CASREACT COPYRIGHT 2005 ACS on STN

1. Et3N, Pyridine

91%

REF: Journal of the American Chemical Society, 125(44), 13427-13441; 2003

RX(3) OF 66

REF: Tetrahedron Letters, 44(37), 6983-6985; 2003

L3 ANSWER 5 OF 48 CASREACT COPYRIGHT 2005 ACS on STN

RX(2) OF 6

REF: Journal of Biological Chemistry, 278(37), 35079-35085; 2003

L3 ANSWER 6 OF 48 CASREACT COPYRIGHT 2005 ACS on STN

RX(4) OF 21

F3CCO2H, Et3N, CH2C12

REF: Journal of Labelled Compounds & Radiopharmaceuticals, 45(11), 943-953; 2002

L3 ANSWER 7 OF 48 CASREACT COPYRIGHT 2005 ACS on STN

REF: Bioorganic & Medicinal Chemistry Letters, 12(21), 3229-3233; 2002

L3 ANSWER 8 OF 48 CASREACT COPYRIGHT 2005 ACS on STN

RX(8) OF 145

EtN(Pr-i)2, Pyridine

RX(8) OF 145

REF: Nucleic Acids Research, 30(13), 3005-3014; 2002

L3 ANSWER 9 OF 48 CASREACT COPYRIGHT 2005 ACS on STN

RX(4) OF 79

REF: Bioorganic & Medicinal Chemistry, 10(6), 1865-1871; 2002

L3 ANSWER 10 OF 48 CASREACT COPYRIGHT 2005 ACS on STN

REF: Journal of Labelled Compounds & Radiopharmaceuticals, 44(11), 763-783; 2001

L3 ANSWER 11 OF 48 CASREACT COPYRIGHT 2005 ACS on STN

RX(22) OF 44

REF: Bioorganic & Medicinal Chemistry Letters, 11(13), 1671-1673;

2001

NOTE: no exptl. detail, reactant assumed

L3 ANSWER 12 OF 48 CASREACT COPYRIGHT 2005 ACS on STN

RX(9) OF 10

NO2

$$+ \text{HO-CH}_2\text{-CH-CH}_2\text{-Ph} + \text{C1-C-NHPh}_2$$

(step 1) (step 5)

REF: Tetrahedron Letters, 42(13), 2443-2446; 2001 NOTE: solid-supported reaction, combinatorial

L3 ANSWER 13 OF 48 CASREACT COPYRIGHT 2005 ACS on STN

REF: Tetrahedron, 57(18), 4035-4038; 2001

L3 ANSWER 14 OF 48 CASREACT COPYRIGHT 2005 ACS on STN

RX(5) OF 16 - REACTION DIAGRAM NOT AVAILABLE

- L3 ANSWER 15 OF 48 CASREACT COPYRIGHT 2005 ACS on STN
- * STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY AVAILABLE VIA OFFLINE PRINT *
- * STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY AVAILABLE VIA OFFLINE PRINT *
- L3 ANSWER 16 OF 48 CASREACT COPYRIGHT 2005 ACS on STN

RX(7) OF 19

REF: Eur. Pat. Appl., 1016653, 05 Jul 2000

L3 ANSWER 17 OF 48 CASREACT COPYRIGHT 2005 ACS on STN

RX(3) OF 9

$$H_2N$$
 O

 $N-C-C1$
 H_2N
 H_2N

HCl (step 2)

REF: Journal of the Chinese Chemical Society (Taipei), 47(1), 227-240; 2000

L3 ANSWER 18 OF 48 CASREACT COPYRIGHT 2005 ACS on STN

REF: PCT Int. Appl., 9425477, 10 Nov 1994

L3 ANSWER 19 OF 48 CASREACT COPYRIGHT 2005 ACS on STN

RX(2) OF 6

REF: Godishnik na Sofiiskiya Universitet Sv. Kliment Okhridski, Khimicheski Fakultet, 1984, 78,, 279-83; 1988

L3 ANSWER 20 OF 48 CASREACT COPYRIGHT 2005 ACS on STN

RX(20) OF 33

REF: Archiv der Pharmazie (Weinheim, Germany), 323(6), 367-73; 1990

L3 ANSWER 21 OF 48 CASREACT COPYRIGHT 2005 ACS on STN

RX(18) OF 119

REF: Journal fuer Praktische Chemie (Leipzig), 332(1), 83-92; 1990 NOTE: either solvent used

L3 ANSWER 22 OF 48 CASREACT COPYRIGHT 2005 ACS on STN

REF: Zhurnal Obshchei Khimii, 59(4), 891-5; 1989

L3 ANSWER 23 OF 48 CASREACT COPYRIGHT 2005 ACS on STN RX(1) OF 1 - REACTION DIAGRAM NOT AVAILABLE

L3 ANSWER 24 OF 48 CASREACT COPYRIGHT 2005 ACS on STN

RX(38) OF 189 - 2 STEPS

REF: Journal of Heterocyclic Chemistry, 26(1), 231-6; 1989

L3 ANSWER 25 OF 48 CASREACT COPYRIGHT 2005 ACS on STN

RX(1) OF 4

$$\begin{array}{ccc}
& & & & & & & & \\
\parallel & & & & & & & & \\
C1-C-NPh_2 & & & & & & & \\
\end{array}
\xrightarrow{PhNH2}
\xrightarrow{PhNH-C-NPh_2}$$

REF: U.S., 4797419, 10 Jan 1989

L3 ANSWER 26 OF 48 CASREACT COPYRIGHT 2005 ACS on STN

REF: European Journal of Medicinal Chemistry, 22(6), 511-20; 1987

RX(4) OF 6

stereoisomers

REF: Nucleosides & Nucleotides, 7(1), 37-43; 1988 NOTE: 74% Overall

L3 ANSWER 28 OF 48 CASREACT COPYRIGHT 2005 ACS on STN

REF: Canadian Journal of Chemistry, 65(6), 1436-7; 1987

L3 ANSWER 29 OF 48 CASREACT COPYRIGHT 2005 ACS on STN

REF: Monatshefte fuer Chemie, 118(2), 217-28; 1987

L3 ANSWER 30 OF 48 CASREACT COPYRIGHT 2005 ACS on STN

REF: PCT Int. Appl., 8702357, 23 Apr 1987

RX(29) OF 327

REF: Journal of Medicinal Chemistry, 30(7), 1166-76; 1987

L3 ANSWER 32 OF 48 CASREACT COPYRIGHT 2005 ACS on STN

1. (Bu3Sn)2O, Benzene
2. Pyridine

REF: Tetrahedron Letters, 27(34), 4047-50; 1986

L3 ANSWER 33 OF 48 CASREACT COPYRIGHT 2005 ACS on STN

RX(7) OF 28

REF: Zhurnal Organicheskoi Khimii, 22(8), 1706-11; 1986

L3 ANSWER 34 OF 48 CASREACT COPYRIGHT 2005 ACS on STN

RX(16) OF 45

REF: Journal fuer Praktische Chemie (Leipzig), 328(3), 401-6; 1986

L3 ANSWER 35 OF 48 CASREACT COPYRIGHT 2005 ACS on STN

RX(14) OF 43

87%

REF: Journal fuer Praktische Chemie (Leipzig), 328(3), 393-400; 1986

L3 ANSWER 36 OF 48 CASREACT COPYRIGHT 2005 ACS on STN

RX(2) OF 27

REF: Journal of Organic Chemistry, 51(23), 4483-5; 1986

L3 ANSWER 37 OF 48 CASREACT COPYRIGHT 2005 ACS on STN

RX(10) OF 46

REF: Journal of Medicinal Chemistry, 30(1), 62-7; 1987

L3 ANSWER 38 OF 48 CASREACT COPYRIGHT 2005 ACS on STN

RX(1) OF 1

$$\begin{array}{c|cccc}
\text{OH} & & & & & & & & \\
\text{CH}_2-\text{CH}-\text{CH}_2-\text{OMe} & & & & & & \\
N & & + & & & & \\
N & & & \text{Cl}-\text{C-NHPh} & & & & \\
\end{array}$$

REF: Czech., 228301, 15 Sep 1986

L3 ANSWER 39 OF 48 CASREACT COPYRIGHT 2005 ACS on STN

RX(48) OF 169

REF: Journal of Heterocyclic Chemistry, 22(5), 1383-8; 1985

L3 ANSWER 40 OF 48 CASREACT COPYRIGHT 2005 ACS on STN

REF: Tetrahedron Letters, 26(43), 5273-6; 1985

L3 ANSWER 41 OF 48 CASREACT COPYRIGHT 2005 ACS on STN

REF: Ger. Offen., 3207474, 15 Sep 1983

L3 ANSWER 42 OF 48 CASREACT COPYRIGHT 2005 ACS on STN

RX(2) OF 6

REF: Ger. Offen., 3229589, 24 Feb 1983

L3 ANSWER 43 OF 48 CASREACT COPYRIGHT 2005 ACS on STN

RX(1) OF 3

EtO- C-
$$CH_2$$
- CH_2 - CH -

RX(1) OF 3

REF: Jpn. Kokai Tokkyo Koho, 57024340, 08 Feb 1982, Showa

RX(2) OF 2

REF: Eur. Pat. Appl., 46557, 03 Mar 1982

L3 ANSWER 45 OF 48 CASREACT COPYRIGHT 2005 ACS on STN

RX(16) OF 87

$$\begin{array}{c} O \\ C1-C-NH \\ O-CH_2-CH_2 \end{array} \qquad \begin{array}{c} Me \\ C1CO2CC13 \\ O-CH_2-CH_2 \end{array}$$

REF: Eur. Pat. Appl., 3835, 05 Sep 1979

L3 ANSWER 46 OF 48 CASREACT COPYRIGHT 2005 ACS on STN

RX(19) OF 23 - 2 STEPS

REF: Journal of Heterocyclic Chemistry, 16(2), 321-5; 1979

L3 ANSWER 47 OF 48 CASREACT COPYRIGHT 2005 ACS on STN

REF: Journal of Organic Chemistry, 43(23), 4530-2; 1978

L3 ANSWER 48 OF 48 CASREACT COPYRIGHT 2005 ACS on STN

RX(1) OF 1

888

REF: Journal of Medicinal & Pharmaceutical Chemistry, 3,, 99-110;

1961

NOTE: Classification: N-Acylation; # Conditions: EtOH Rf 16h

=>